ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1859

Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study

Adam Geressu1 and Marwan Bukhari2, 1Royal Lancaster Infirmary, Lancaster, United Kingdom, 2British Society for Rheumatology, London, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Bone density, Dual energy x-ray absorptiometry (DEXA), giant cell arteritis, glucocorticoids

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine or the hip. The aim of this study was to examine bone mineral density (BMD) of the lumbar spine, left neck of femur, right neck of femur, left total hip and right total hip in patients diagnosed with GCA being treated with GC.

Methods: We collected data from patients with GCA who were referred to the rheumatology department at two hospitals in the North West of England between 2010 and 2019. Patient’s details recorded at time of scan included age, gender, Body Mass Index (BMI), and drug treatment, specifically GC use. Dual X-Ray absorptiometry (DEXA) assessed BMD in the spine (mean of L1-L4 vertebrae), left femoral neck, right femoral neck, left total hip and right total hip. Two patient groups were identified, patients with GCA on current GC (cases) and matched 1:4 to those referred for a DEXA scan with no reason for scanning (controls). The prevalence of BMD in each group was compared by a two sample t-test. A comparison was made between the two groups using logistic regression adjusting for age and gender.

Results: A total of 309 patients were included. 61 of these patients were diagnosed with GCA and had a DEXA scan performed (48 females, 13 males). In comparison the control group had 248 patients (196 females, 52 males). Patients diagnosed with GCA had higher values of BMD than patients not diagnosed with GCA that were of the same age and gender. This gave an odds ratio (OR) of 0.68(95%CI 0.18; 2.64) at the lumbar spine, OR of 2.05(95%CI 0.22; 19.45) at the left femoral neck, OR of 3.27(95%CI 0.33; 32.73) at the right femoral neck, OR of 4.26(95%CI 0.27; 66.52) at the left total hip and OR of 8.01(95%CI 0.43; 147.91) at the right total hip. The numeric values of BMD at all sites were higher in the patients with GCA than in the controls.

Conclusion: The study has shown a surprising protective effect GCA has on BMD. Patients diagnosed with GCA receiving GC treatment have shown to have a higher BMD compared to patients without GCA of the same age and gender. Possible confounders include length of time on steroid when scanned or unmeasured confounders in the controls.


Disclosures: A. Geressu, None; M. Bukhari, None.

To cite this abstract in AMA style:

Geressu A, Bukhari M. Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/bone-mineral-density-in-patients-diagnosed-with-giant-cell-arteritis-taking-glucocorticoids-a-case-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bone-mineral-density-in-patients-diagnosed-with-giant-cell-arteritis-taking-glucocorticoids-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology